OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Munshi on Latest Treatment Developments in Multiple Myeloma

August 16th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the latest treatment developments for patients with multiple myeloma.

Dr. Roschewski on the Treatment of Burkitt Lymphoma in Adults

August 16th 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the treatment of Burkitt lymphoma in adult patients.

Dr. Kolberg Discusses Next Steps with ABP 980

August 16th 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses next steps with the trastuzumab (Herceptin) biosimilar ABP 980.

Dr. Bunn on TMB as a Biomarker in Small Cell Lung Cancer

August 15th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses tumor mutational burden as a biomarker in small cell lung cancer.

Dr. Jotte on the Optimal Frequency of Lung Cancer Screening

August 15th 2018

Robert M. Jotte, MD, PhD, medical director and co-chair of the USON Thoracic Committee at Rocky Mountain Cancer Centers, discusses the optimal frequency of lung cancer screening.

Dr. Ahn on Biomarker-Driven Strategies in Gastric/GEJ Cancers

August 15th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses biomarker-driven strategies in gastric and gastroesophageal junction (GEJ) cancers.

Dr. Feliciano on ROS1-Targeted Therapy in NSCLC

August 15th 2018

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses ROS1-targeted therapy in patients with non–small cell lung cancer (NSCLC).

Dr. Ligibel on Patient Education to Avoid Breast Cancer Recurrence

August 15th 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women's Cancer at the Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the resources available for patients to educate themselves on avoiding breast cancer recurrence.

Dr. Formenti Discusses Immunology in Breast Cancer Treatment

August 15th 2018

Silvia Chiara Formenti, MD, chairman, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses immunology in the breast cancer treatment landscape.

Dr. George Discusses an Analysis of the S-TRAC Study in RCC

August 15th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses an analysis of the S-TRAC study in renal cell carcinoma.

Dr. Garcia-Sanz on Combination Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma

August 15th 2018

Ramon Garcia-Sanz, MD, PhD, clinician, department of Hematology, Hospital Universitario de Salamanca, discusses combination chemotherapy in patients with Hodgkin lymphoma.

Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC

August 14th 2018

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).

Dr. Tripathy on the Progression of Biosimilars in Oncology

August 14th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the progression of biosimilars in oncology.

Dr. Liu on Resistance Mechanisms in EGFR-Mutant Lung Cancer

August 14th 2018

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses resistance mechanisms in EGFR-mutant lung cancer.

Dr. Turner on Important Steps for Genomic Profiling in Gynecologic Malignancies

August 14th 2018

Taylor Turner, MD, fellow, University of Alabama at Birmingham School of Medicine, discusses important steps to implement a genomic profiling program for gynecologic malignancies.

Dr. Ulm on Trial for Postoperative Pain Management in Gynecological Cancer

August 14th 2018

Michael Ulm, MD, fellow, University of Tennessee Health Science Center, West Cancer Center, discusses the rationale and results of a trial for postoperative pain management in gynecological cancer.

Dr. Choyke on Differences Between PET Scans in Prostate Cancer

August 14th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the differences between PET scans in prostate cancer.

Dr. Brander Discusses the Frontline Treatment of CLL

August 14th 2018

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Bekaii-Saab Discusses the Evolution of Treatment for Pancreatic Cancer

August 14th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the evolution of treatment for patients with pancreatic cancer.

Dr. O'Neil on Standard of Care in Muscle-Invasive Bladder Cancer

August 14th 2018

Brock O’Neil, MD, assistant professor, Division of Urology, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the current standard of care in muscle-invasive bladder cancer.